RxDoctor Payments Data

Donald Miller, MD

Rheumatology · Bryn Mawr, PANPI 1376569418

Payments from drug & device makers

$16,391in general payments, 2019–2025

Across 729 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • UCB, Inc.$900
  • Novartis$854
  • Pfizer$792
  • plus $8K from 45 others

What the payments were for

  • Food & beverage$15,62995%
  • Education$7625%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,391 in reported general payments places this provider in the 70th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$3,324,132
Medicare patients
575
Services billed
290,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab19$228,726
RinvoqUpadacitinib33$215,263
Xeljanz XrTofacitinib Citrate19$107,620
KevzaraSarilumab11$64,418
XeljanzTofacitinib Citrate11$59,471
MethotrexateMethotrexate Sodium611$16,361
RasuvoMethotrexate/Pf16$12,696
Hydroxychloroquine Sulfate292$11,577
XiidraLifitegrast12$7,937
Leflunomide124$7,057
Celecoxib157$5,017
Colchicine44$4,392
Prednisone448$3,995
Diclofenac Sodium43$3,610
Sulfasalazine84$2,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,865$215,26333 claims
SanofiKevzara$170$64,41811 claims
PfizerXeljanz$792$59,47111 claims
Medexus Pharma, Inc.Rasuvo$42$12,69616 claims
Scilex Pharmaceuticals Inc.Colchicine$43$4,39244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 351 rheumatology providers in Pennsylvania.

Other rheumatology in Bryn Mawr

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →